生物科技公司Erasca, INC. (ERAS) 今日盘前股价大跌34.78%，引发了市场的广泛关注。
消息面上，此次股价剧烈波动主要源于两大利空因素的叠加。首先，同行公司Revolution Medicines通过SEC文件指控Erasca涉嫌不当使用与其核心药物ERAS-0015相关的商业秘密，并要求其停止该药物在美国境内的所有研发活动。这一突如其来的法律纠纷为Erasca的核心管线前景蒙上了巨大的不确定性阴影。
与此同时，ERAS-0015的一期临床试验数据读出时间已明确为不迟于5月中旬。关键催化剂窗口的迫近，与当前的知识产权争议相互交织，显著加剧了市场的多空分歧与担忧情绪。盘前的暴跌反映出市场正在对潜在的诉讼风险及研发受阻的可能性进行紧急重估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.